Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,400,056 papers from all fields of science
Search
Sign In
Create Free Account
CBS 1108
Known as:
CBS-1108
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
2-acetylthiophene-2-thiazolylhydrazone
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
New Pyrazolylhydrazone Derivatives as Inhibitors of Platelet Aggregation
I. Silveira
,
L. G. Paulo
,
A. Miranda
,
S. O. Rocha
,
A. Freitas
,
E. Barreiro
The Journal of pharmacy and pharmacology
1993
Corpus ID: 34398811
Abstract— A series of 5‐pyrazolylhydrazone derivatives was designed to be mixed hybrid isosteres of both BW755C and CBS‐1108…
Expand
1991
1991
Substituted pyrazolylhydrazones: a new class of platelet aggregation inhibitors.
I. Silveira
,
L. G. Paulo
,
A. Miranda
,
S. O. Rocha
,
A. Freitas
,
E. Barreiro
Brazilian journal of medical and biological…
1991
Corpus ID: 28226006
A series of 5-pyrazolylhydrazone derivatives (I) were designed to be mixed hybrid isosteres of both BW-755C and CBS-1108 which…
Expand
1985
1985
Anti-inflammatory activity of a dual inhibitor of cyclooxygenase and lipoxygenase pathways, CBS-1108 (2-acetylthiophene-2-thiazolylhydrazone).
D. Sincholle
,
C. Bertez
,
A. Legrand
,
J. Conduzorgues
,
C. Bonne
Arzneimittel-Forschung
1985
Corpus ID: 27636471
Anti-inflammatory therapy is actually devolved to glucocorticoids which prevent the release of arachidonic acid from…
Expand
1984
1984
Dual inhibition of cyclooxygenase and lipoxygenase by 2-acetylthiophene 2-thiazolylhydrazone (CBS-1108) and effect on leukocyte migration in vivo.
C. Bertez
,
M. Miquel
,
C. Coquelet
,
D. Sincholle
,
C. Bonne
Biochemical Pharmacology
1984
Corpus ID: 32163320
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE